Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

Exclusion Criteria

• •1. The subject is in a hypercoagulable state.
• •2. The subject has known bleeding diathesis.
• •3. The subject has insufficient cardiac output to support a native fistula in the opinion of the Investigator.
• •4. Known history of active intravenous drug abuse.
• •5. "Planned" major surgical procedure within 6 months following index procedure or major surgery within 30 days prior to index procedure.
• •6. The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.
• •7. The subject has known adverse effects to sedation and/or anesthesia which cannot be adequately pre-medicated.
• •8. Evidence of active infection on the day of the index procedure (temperature of ≥ 38.0° Celsius and/ or WBC of ≥ 12,000 cells/ μL, if collected).
• •9. The subject has another medical condition, which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
• •10. The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.
• •11. The subject has central venous stenosis or central vein narrowing \> 50% based on imaging on the same side as the planned endoAVF creation.
• •12. Absence of a proximal forearm perforating vein feeding the target cannulation vein(s) from the target creation site via Duplex Ultrasound (DUS) or Venography.
• •13. Occlusion or stenosis \> 50% of target cannulation vein(s) such as cephalic, median cubital, basilic, etc. assessed via Duplex Ultrasound (DUS) or Venography.
• •14. Significantly compromised venous or arterial flow in the treatment arm as determined by Investigator and Duplex Ultrasound (DUS) or Venography.
• •15. Presence of significant calcification at the target endoAVF location that could potentially impact the effectiveness of endoAVF creation as determined by the Investigator.